Pediatric 131I-MIBG Therapy for Neuroblastoma: Whole-Body 131I-MIBG Clearance, Radiation Doses to Patients, Family Caregivers, Medical Staff, and Radiation Safety Measures

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorWILLEGAIGNON, Jose
dc.contributor.authorCREMA, Karin Paola
dc.contributor.authorOLIVEIRA, Nathalie Canhameiro
dc.contributor.authorPELISSONI, Rogerio Alexandre
dc.contributor.authorCOURA-FILHO, George Barberio
dc.contributor.authorSAPIENZA, Marcelo Tatit
dc.contributor.authorBUCHPIGUEL, Carlos Alberto
dc.date.accessioned2018-09-13T15:23:04Z
dc.date.available2018-09-13T15:23:04Z
dc.date.issued2018
dc.description.abstractPurpose I-131-metaiodobenzylguanidine (I-131-MIBG) has been used in the diagnosis and therapy of neuroblastoma in adult and pediatric patients for many years. In this study, we evaluated whole-body I-131-MIBG clearance and radiation doses received by patients, family caregivers, and medical staff to establish appropriate radiation safety measures to be used in therapy applications. Methods Research was focused on 23 children and adolescents with metastatic neuroblastoma, with ages ranging from 1.8 to 13 years, being treated with I-131-MIBG. Based on measured external dose rates from patients, dosimetric data to patients, family members, and others were calculated. Results The mean SD I-131-MIBG activity administered was 8.55 +/- 1.69 GBq. Percent whole-body retention rates of I-131-MIBG at 24, 48, and 72 hours after administration were 48% +/- 7%, 23% +/- 7%, and 12% +/- 6%, with a whole-body I-131-MIBG effective half-life of 23 +/- 5 hours for all patients. The mean doses for patients were 0.234 +/- 0.096 mGyMBq(-1) to red-marrow and 0.251 +/- 0.101 mGyMBq(-1) to whole body. The maximum potential radiation doses transmitted by patients to others at 1.0 m was estimated to be 11.9 +/- 3.4 mSv, with 97% of this dose occurring over 120 hours after therapy administration. Measured mean dose received by the 22 family caregivers was 1.88 +/- 1.85 mSv, and that received by the 19 pediatric physicians was 43 +/- 51 Sv. Conclusion In this study, we evaluated the whole-body clearance of I-131-MIBG in 23 pediatric patients, and the radiation doses received by family caregivers and medical staff during these therapy procedures, thus facilitating the establishment of radiation safety measures to be applied in pediatric therapy.
dc.description.indexMEDLINE
dc.identifier.citationCLINICAL NUCLEAR MEDICINE, v.43, n.8, p.572-578, 2018
dc.identifier.doi10.1097/RLU.0000000000002158
dc.identifier.eissn1536-0229
dc.identifier.issn0363-9762
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/28083
dc.language.isoeng
dc.publisherLIPPINCOTT WILLIAMS & WILKINS
dc.relation.ispartofClinical Nuclear Medicine
dc.rightsrestrictedAccess
dc.rights.holderCopyright LIPPINCOTT WILLIAMS & WILKINS
dc.subjectneuroblastoma
dc.subjectI-131-MIBG
dc.subjecttherapy
dc.subjectradiation exposure
dc.subjectdosimetry
dc.subject.otheri-131 metaiodobenzylguanidine
dc.subject.otherneuroendocrine tumors
dc.subject.othercancer-therapy
dc.subject.otherthyroid-cancer
dc.subject.otheri-131-metaiodobenzylguanidine
dc.subject.otherdosimetry
dc.subject.otherchildren
dc.subject.othermibg
dc.subject.otheriodine-131-metaiodobenzylguanidine
dc.subject.otherexposure
dc.subject.wosRadiology, Nuclear Medicine & Medical Imaging
dc.titlePediatric 131I-MIBG Therapy for Neuroblastoma: Whole-Body 131I-MIBG Clearance, Radiation Doses to Patients, Family Caregivers, Medical Staff, and Radiation Safety Measures
dc.typearticle
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.citation.scopus9
hcfmusp.contributor.author-fmusphcJOSE WILLEGAIGNON DE AMORIM DE CARVALHO
hcfmusp.contributor.author-fmusphcKARIN PAOLA CREMA
hcfmusp.contributor.author-fmusphcNATHALIE CANHAMEIRO OLIVEIRA
hcfmusp.contributor.author-fmusphcROGERIO ALEXANDRE PELISSONI
hcfmusp.contributor.author-fmusphcGEORGE BARBERIO COURA FILHO
hcfmusp.contributor.author-fmusphcMARCELO TATIT SAPIENZA
hcfmusp.contributor.author-fmusphcCARLOS ALBERTO BUCHPIGUEL
hcfmusp.description.beginpage572
hcfmusp.description.endpage578
hcfmusp.description.issue8
hcfmusp.description.volume43
hcfmusp.origemWOS
hcfmusp.origem.pubmed29916922
hcfmusp.origem.scopus2-s2.0-85050167058
hcfmusp.origem.wosWOS:000439523100014
hcfmusp.publisher.cityPHILADELPHIA
hcfmusp.publisher.countryUSA
hcfmusp.relation.referenceBOLSTER AA, 1995, BRIT J RADIOL, V68, P481, DOI 10.1259/0007-1285-68-809-481
hcfmusp.relation.referenceChu BP, 2016, PEDIATR BLOOD CANCER, V63, P801, DOI 10.1002/pbc.25892
hcfmusp.relation.referenceCougnenc O, 2017, RADIAT PROT DOSIM, V173, P395, DOI 10.1093/rpd/ncw030
hcfmusp.relation.referenceFIELDING SL, 1991, EUR J NUCL MED, V18, P308, DOI 10.1007/BF02285457
hcfmusp.relation.referenceGains JE, 2015, PEDIATR BLOOD CANCER, V62, P235, DOI 10.1002/pbc.25250
hcfmusp.relation.referenceHan S, 2017, CLIN NUCL MED, V42, P271, DOI 10.1097/RLU.0000000000001546
hcfmusp.relation.referenceHjornevik T, 2015, J NUCL MED RAD THER, V6, P1
hcfmusp.relation.referenceHOEFNAGEL CA, 1987, J NUCL MED, V28, P308
hcfmusp.relation.referenceInternational Commission on Radiological Protection, 2004, ICRP PUBL, V94
hcfmusp.relation.referenceMarkelewicz RJ, 2013, CLIN NUCL MED, V38, P604, DOI 10.1097/RLU.0b013e31829af3c8
hcfmusp.relation.referenceMatthay KK, 2006, J CLIN ONCOL, V24, P500, DOI 10.1200/JCO.2005.03.6400
hcfmusp.relation.referenceMinguez P, 2015, MED PHYS, V42, P3969, DOI 10.1118/1.4921807
hcfmusp.relation.referenceMonsieurs M, 2002, EUR J NUCL MED MOL I, V29, P1581, DOI 10.1007/s00259-002-0973-4
hcfmusp.relation.referenceRadiological Protection Institute of Ireland, 2009, 0901 RPII NUCL EN BO
hcfmusp.relation.referenceShulkin BL, 1998, J NUCL MED, V39, P679
hcfmusp.relation.referenceStabin MG, 2008, FUNDAMENTALS NUCL ME
hcfmusp.relation.referenceTrieu M, 2016, PEDIATR BLOOD CANCER, V63, P436, DOI 10.1002/pbc.25816
hcfmusp.relation.referenceTristam M, 1996, J NUCL MED, V37, P1058
hcfmusp.relation.referenceWafelman AR, 1997, EUR J NUCL MED, V24, P544
hcfmusp.relation.referenceWillegaignon J, 2006, HEALTH PHYS, V91, P119, DOI 10.1097/01.HP.0000202232.98823.87
hcfmusp.relation.referenceWillegaignon J, 2006, HEALTH PHYS, V91, P123, DOI 10.1097/01.HP.0000206041.25242.c0
hcfmusp.relation.referenceWillegaignon J, 2006, HEALTH PHYS, V91, P624, DOI 10.1097/01.HP.0000225467.10064.34
hcfmusp.scopus.lastupdate2024-05-10
relation.isAuthorOfPublicationa4442ffe-9dfc-4821-a375-0f6358f38ba2
relation.isAuthorOfPublication91eccf89-4a53-4f82-a6f4-4f3a6d1b5ac5
relation.isAuthorOfPublicationfc310656-2ebe-4e30-a9da-a167959cec68
relation.isAuthorOfPublication566c191a-8594-444a-96aa-98c9f1048f39
relation.isAuthorOfPublication5904d222-2a67-4e8f-b3a4-4235079fa385
relation.isAuthorOfPublication1b6d30d8-f675-4713-af58-f7b2b1479ddd
relation.isAuthorOfPublication6fcbbc21-1ba0-4023-a2cd-0e709b22f5c3
relation.isAuthorOfPublication.latestForDiscoverya4442ffe-9dfc-4821-a375-0f6358f38ba2
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_WILLEGAIGNON_Pediatric_131IMIBG_Therapy_for_Neuroblastoma_WholeBody_131IMIBG_Clearance_2018.PDF
Tamanho:
389.04 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MDR
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/InRad
Artigos e Materiais de Revistas Científicas - LIM/43
Artigos e Materiais de Revistas Científicas - ODS/03